Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAG1 | P54619 | 2/20 | 0.51 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.51 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.51 |
| ▸ | HAO1 | Q9UJM8 | 2/20 | 0.49 |
| ▸ | ALPL | P05186 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.43 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.43 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.43 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21296956 | 0.96 | HAO1 (0.52) | PRKAG1PRKAA1PRKAB1HAO1ALPL | |
| SCHEMBL21296952 | 0.92 | RXRA (0.51) | PRKAG1PRKAA1PRKAB1HAO1ALPL | |
| SCHEMBL21296929 | 0.89 | PIN1 (0.49) | PRKAG1PRKAA1PRKAB1HAO1ALPL | |
| SCHEMBL29799086 | 0.89 | PRKAG1 (0.50) | PRKAG1PRKAA1PRKAB1HAO1ALPL | |
| SCHEMBL21296954 | 0.89 | PRKAG1 (0.50) | PRKAG1PRKAA1PRKAB1HAO1ALPL | |
| SCHEMBL21296970 | 0.89 | ALPL (0.42) | PRKAG1PRKAA1PRKAB1HAO1ALPL | |
| SCHEMBL21296854 | 0.88 | HAO1 (0.44) | PRKAG1PRKAA1PRKAB1HAO1MCL1 | |
| SCHEMBL23001821 | 0.88 | HAO1 (0.65) | HAO1 | |
| SCHEMBL21296848 | 0.87 | PRKAG1 (0.45) | PRKAG1PRKAA1PRKAB1HAO1ALPL | |
| SCHEMBL23319968 | 0.86 | HAO1 (0.50) | PRKAG1PRKAA1PRKAB1HAO1ALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143491-A1 | TRIAZOLE GLYCOLATE OXIDASE INHIBITORS | PHOENIX TISSUE REPAIR, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230143491-A1 | TRIAZOLE GLYCOLATE OXIDASE INHIBITORS | PHOENIX TISSUE REPAIR, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230143491-A1 | TRIAZOLE GLYCOLATE OXIDASE INHIBITORS | PHOENIX TISSUE REPAIR, INC. | 2023-05-11 | — | — | US | disclosed |
| US-11389456-B2 | Compounds and methods for treating oxalate-related diseases | OXALURX, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| US-20210403439-A1 | TRIAZOLE GLYCOLATE OXIDASE INHIBITORS | VENTHERA, INC. | 2021-12-30 | — | — | US | disclosed |
| EP-3817816-A1 | TRIAZOLE GLYCOLATE OXIDASE INHIBITORS | Orfan Biotech Inc. (US) | 2021-05-12 | — | — | EP | disclosed |
| US-20200390778-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. | 2020-12-17 | — | — | US | disclosed |
| US-20200390778-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. | 2020-12-17 | — | — | US | disclosed |
| WO-2019165159-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. (US) | 2019-08-29 | — | — | WO | disclosed |
| WO-2019165159-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. (US) | 2019-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143491-A1 | TRIAZOLE GLYCOLATE OXIDASE INHIBITORS | XDH, DUOX1, PNPO | PRKAG1 2945/4885PRKAA1 2067/4885PRKAB1 3254/4885 |
| US-20200390778-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | XDH, PNPO, LOX | PRKAG1 2580/4885PRKAA1 2860/4885PRKAB1 2716/4885 |
| US-11389456-B2 | Compounds and methods for treating oxalate-related diseases | XDH, PNPO, LOX | PRKAG1 2580/4885PRKAA1 2860/4885PRKAB1 2716/4885 |
| US-20210403439-A1 | TRIAZOLE GLYCOLATE OXIDASE INHIBITORS | XDH, DUOX1, PNPO | PRKAG1 2945/4885PRKAA1 2067/4885PRKAB1 3254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.